Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Emisphere Reaches Novo Nordisk Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Emisphere Reaches Novo Nordisk Milestone

Novo Nordisk has initiated its first Phase I trial with a long-acting oral GLP-1 analogue (NN9924), triggering a $2 million milestone payment to development partner Emisphere Technologies.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novo Nordisk has initiated its first Phase I trial with a long-acting oral GLP-1 analogue (NN9924), triggering a $2 million milestone payment to development partner Emisphere Technologies. GLP-1 (Glucagon-Like Peptide-1) is a natural hormone involved in controlling blood sugar levels. GLP-1 secretion is often impaired in people with Type 2 Diabetes.

NN9924 is formulated using Emisphere’s Eligen Technology to facilitate absorption from the gut in order to obtain adequate bioavailability. The trial will investigate the safety, tolerability and bioavailability of NN9924 in healthy volunteers and will enroll approximately 155 people. Results are expected in 2011.

“We still have a long road with many challenges ahead of us before an insulin pill or a GLP-1 pill becomes a reality,” said Peter Kurtzhals, senior vice president and head of diabetes research at Novo Nordisk. “But with the progress we have made so far I am convinced it is only a matter of time.”

Michael V. Novinski, president and chief executive officer, Emisphere Technologies, said, “This milestone reflects a major achievement for our program and partnership with Novo Nordisk and is one small but significant step forward in the development of a successful treatment for Type 2 Diabetes. As a company, we are extremely encouraged by the progress to date and look forward to the future and the potential benefits this program may bring to the millions of patients being treated for this disease.”

In June 2008, the two companies entered into a development and license agreement to develop and commercialize oral formulations of Novo Nordisk’s GLP-1 analogues using Emisphere’s Eligen Technology. This is the first development milestone achieved under this agreement.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters